S 17092-1

structure in first source; inhibits proline endopeptidase

Also Known As:

(2S,3aS,7aS)-1-(((R,R)-2-phenylcyclopropyl)carbonyl)-2-((thiazolidin-3-yl)carbonyl)octahydro-1H-indole; S 17092; S17092-1

Networked: 5 relevant articles (0 outcomes, 0 trials/studies)

1.	Morain, P: 3 articles (05/2005 - 05/2000)
2.	Bellemère, G: 1 article (05/2005)
3.	Jégou, S: 1 article (05/2005)
4.	Vaudry, H: 1 article (05/2005)
5.	Giardiniere, M: 1 article (02/2002)
6.	Schneider, J S: 1 article (02/2002)
7.	Boyer, Pierre-Alain: 1 article (01/2002)
8.	De Nanteuil, Guillaume: 1 article (01/2002)
9.	Guez, David: 1 article (01/2002)
10.	Jochemsen, Roeline: 1 article (01/2002)

1.	Cognitive Dysfunction 01/01/2002 - "Collectively, the preclinical and clinical effects of S 17092 have suggested a promising role for this compound as an agent for the treatment of cognitive disorders associated with cerebral aging." 05/01/2000 - "Further evidence for a dissociation between different forms of mnemonic expressions in a mouse model of age-related cognitive decline: effects of tacrine and S 17092, a novel prolyl endopeptidase inhibitor."
2.	Parkinsonian Disorders (Parkinsonism) 02/01/2002 - "The most effective dose of S 17092 was 3 mg/kg. These results indicate that S 17092 has cognition-enhancing properties in this model of early parkinsonism."
3.	Neurodegenerative Diseases (Neurodegenerative Disease) 05/01/2005 - "Compound S 17092 is a potent and selective inhibitor of prolyl endopeptidase (EC 3.4.21.26, PEP) that may be of therapeutic value for the treatment of memory impairment associated with neurodegenerative diseases. "
4.	Alzheimer Disease (Alzheimer's Disease) 04/21/1999 - "Altogether, we establish that S17092-1 behaves as a highly potent, specific and cell permeant inhibitor of human proline endopeptidase and can be seen as a probe to examine PE contribution in Alzheimer's disease."